Ahmad S. Alotaibi

Dr. Ahmad S. Alotaibi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
AZAdi Zoref-Lorenz
Adi Zoref-Lorenz
JMJun Murakami
Jun Murakami
LHLiron Hofstetter
Liron Hofstetter
SISwaminathan Iyer
Swaminathan Iyer
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
MJMichael B. Jordan
Michael B. Jordan
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening inflammatory syndrome that may complicate hematologic malignancies (HMs). The appropriateness of current criteria for diagnosing HLH in the context of HMs is unknown because they were developed for children with familial HLH (HLH-2004) or derived from adult patient cohorts in which HMs were underrepresented (HScore). Moreover, many features of these criteria may directly reflect the underlying HM rather than an abnormal inflammatory state. To improve and potentially simplify HLH diagnosis in patients with HMs, we studied an international cohort of 225 adult patients with various HMs both with and without HLH and for whom HLH-2004 criteria were available. Classification and regression tree and receiver-operating curve analyses were used to identify the most useful diagnostic and prognostic parameters and to optimize laboratory cutoff values. Combined elevation of soluble CD25 (>3900 U/mL) and ferritin (>1000 ng/mL) best identified HLH-2004–defining features (sensitivity, 84%; specificity, 81%). Moreover, this combination, which we term the optimized HLH inflammatory (OHI) index, was highly predictive of mortality (hazard ratio, 4.3; 95% confidence interval, 3.0-6.2) across diverse HMs. Furthermore, the OHI index identified a large group of patients with high mortality risk who were not defined as having HLH according to HLH-2004/HScore. Finally, the OHI index shows diagnostic and prognostic value when used for routine surveillance of patients with newly diagnosed HMs as well as those with clinically suspected HLH. Thus, we conclude that the OHI index identifies patients with HM and an inflammatory state associated with a high mortality risk and warrants further prospective validation.

31 July 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
BSBachar Samra
Bachar Samra
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
Joseph KhouryJoseph Khoury
Joseph Khoury
FRFarhad Ravandi
Farhad Ravandi
EJElias Jabbour
Elias Jabbour

25 November 2020 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
BSBachar Samra
Bachar Samra
HKHagop M. Kantarjian
Hagop M. Kantarjian
KSKoji Sasaki
Koji Sasaki
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
MKMarina Konopleva
Marina Konopleva
EJElias Jabbour
Elias Jabbour
Background: The addition of tyrosine kinase inhibitors (TKIs) to chemotherapy has dramatically improved outcomes of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). When allogeneic hematopoietic stem cell transplant (HSCT) is performed, maintenance TKI is generally given for a fixed duration. However, the optimal duration of TKI outside of HSCT remains unknown, and the common practice is to continue indefinitely. Here, we report characteristics and outcomes of 9 patients treated with chemotherapy + TKI without HSCT and later discontinued TKI. Methods: Among 188 patients with Ph-positive ALL who did not undergo HSCT, 9 of them discontinued maintenance TKI mainly due to side effects. Patients were closely monitored with serial PCR testing for the BCR-ABL1 transcript. Major molecular response (MMR) was defined as BCR-ABL1 transcript ≤0.1% on the international scale for p210 transcripts and a 3-log reduction from baseline for p190 transcripts. Deep molecular remission (DMR) was defined as the absence of quantifiable BCR-ABL1 transcripts with a sensitivity of 0.01%. Molecular relapse was defined as loss of MMR. Treatment-free remission (TFR) was defined from time of TKI discontinuation to molecular relapse, last follow-up, or death from any cause. Results: At the time of TKI discontinuation, transcript level was undetected in 6 patients, <0.01% in 2 patients, and 0.01% in another patient. Prior to discontinuation, the median duration of TKI therapy and of DMR was 70 and 47 months, respectively. No morphological relapse occurred. Three patients (33%) had molecular relapse at a median of 6 months. All 3 resumed TKI therapy, and 2 of them regained DMR after a median of 13 months. After a median follow-up of 49 months, the median TFR was not reached, and the 4-year TFR rate was 65%. The median duration of DMR in patients with and without molecular relapse was 22 and 58 months, respectively (p = 0.096). Conclusion: TKI discontinuation outside of HSCT in Ph-positive ALL in the setting of compelling toxicity may be safe only among a highly selected group of patients with deep and prolonged DMR undergoing close and frequent monitoring. Validation of these findings in prospective clinical trials is highly needed.

13 July 2022 in Transplant Infectious Disease
Verified
Journal Article
Closed access
SPShruti Prem
Shruti Prem
MRMats Remberger
Mats Remberger
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
WLWilson Lam
Wilson Lam
ALArjun Datt Law
Arjun Datt Law
CECynthia Ellison
Cynthia Ellison

1 May 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ASAmy Spallone
Amy Spallone
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
Ying JiangYing Jiang
Ying Jiang
NDNaval Daver
Naval Daver
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis

11 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NBNASIR A BAKSHI
NASIR A BAKSHI
AHAyman Al Hejazi
Ayman Al Hejazi
HAHatim Al-Maghraby
Hatim Al-Maghraby
AMAreej Al Mugairi
Areej Al Mugairi
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
RORobert Ohgami
Robert Ohgami
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive orphan hematopoietic malignancy characterized by cutaneous and systemic hematologic involvement. BPDCN is frequently misidentified, but early, accurate diagnosis is critical to extending patient survival using tagraxofusp, a first-in-class CD123-targeted therapy, and increasing their chances of receiving a potentially curative stem cell transplantation. Cases of BPDCN in countries of the Gulf Cooperation Council are lower than the extrapolated incidence from other geographic locations due to lack of awareness of key diagnostic features, lack of consensus on the minimal phenotype for diagnosis, and lack of local immunohistochemistry testing facilities, contributing to underdiagnosis in this region. Practical recommendations, a streamlined diagnostic panel, and suggested multidisciplinary approaches based on expert experience regarding diagnostic and clinical challenges specific to this region, and a review of the literature are presented here to facilitate diagnosis of BPDCN in this region by primary care physicians, dermatologists, and hematologists.